PDCD1 and cancer: ICIs target immune system activation against cancer cells; specifically, these monoclonal antibodies are cell surface proteins (i.e., cytotoxic T-lymphocyte antigen-4 [CTLA-4]) and programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) (1).